Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCAR-T Cells in r/r B-ALL
NCT05639179Phase 2Recruiting
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of cd19 universal car-t cells in B cell acute lymphoblastic leukemia (B-ALL). Primary endpoints: Dose-limiting toxicity at 28 days and Treatment Related adverse events at 12 months. Started Dec 2022; status: recruiting.
02
Drugs
cd19 universal car-t cells
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT05639179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05639179.